Ryanodine receptors in muscarinic receptor-mediated bronchoconstriction.
Ryanodine receptors (RyRs), intracellular calcium release channels essential for skeletal and cardiac muscle contraction, are also expressed in various types of smooth muscle cells. In particular, recent studies have suggested that in airway smooth muscle cells (ASMCs) provoked by spasmogens, stored calcium release by the cardiac isoform of RyR (RyR2) contributes to the calcium response that leads to airway constriction (bronchoconstriction). Here we report that mouse ASMCs also express the skeletal muscle and brain isoforms of RyRs (RyR1 and RyR3, respectively). In these cells, RyR1 is localized to the periphery near the cell membrane, whereas RyR3 is more centrally localized. Moreover, RyR1 and/or RyR3 in mouse airway smooth muscle also appear to mediate bronchoconstriction caused by the muscarinic receptor agonist carbachol. Inhibiting all RyR isoforms with > or = 200 microM ryanodine attenuated the graded carbachol-induced contractile responses of mouse bronchial rings and calcium responses of ASMCs throughout the range of carbachol used (50 nM to > or = 3 microM). In contrast, inhibiting only RyR1 and RyR3 with 25 microM dantrolene attenuated these responses caused by high (>500 nM) but not by low concentrations of carbachol. These data suggest that, as the stimulation of muscarinic receptor in the airway smooth muscle increases, RyR1 and/or RyR3 also mediate the calcium response and thus bronchoconstriction. Our findings provide new insights into the complex calcium signaling in ASMCs and suggest that RyRs are potential therapeutic targets in bronchospastic disorders such as asthma.
Du
Wanglei
W
Division of Pulmonary, Allergy and Critical Care Medicine, Duke University, Medical Center, Durham, North Carolina, 27710, USA.
Stiber
Jonathan A
JA
Rosenberg
Paul B
PB
Meissner
Gerhard
G
Eu
Jerry P
JP
D000818:Animals; D001921:Brain / Q000378:metabolism; D001980:Bronchi / Q000378:metabolism* / Q000473:pathology / Q000502:physiology; D002118:Calcium / Q000378:metabolism*; D002217:Carbachol / Q000378:metabolism / Q000494:pharmacology; D002462:Cell Membrane / Q000378:metabolism; D002467:Cell Nucleus / Q000378:metabolism; D018679:Cholinergic Agonists / Q000494:pharmacology; D003620:Dantrolene / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D015151:Immunoblotting; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018613:Microscopy, Confocal; D008856:Microscopy, Fluorescence; D008954:Models, Biological; D009119:Muscle Contraction; D009125:Muscle Relaxants, Central / Q000494:pharmacology; D018482:Muscle, Skeletal / Q000378:metabolism; D009130:Muscle, Smooth / Q000187:drug effects / Q000378:metabolism; D020033:Protein Isoforms; D011976:Receptors, Muscarinic / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012433:Ryanodine / Q000494:pharmacology; D019837:Ryanodine Receptor Calcium Release Channel / Q000096:biosynthesis* / Q000737:chemistry / Q000378:metabolism*; D015398:Signal Transduction; D014018:Tissue Distribution
D018679:Cholinergic Agonists; D009125:Muscle Relaxants, Central; D020033:Protein Isoforms; D011976:Receptors, Muscarinic; D019837:Ryanodine Receptor Calcium Release Channel; D012433:Ryanodine; D002217:Carbachol; D003620:Dantrolene; D002118:Calcium